This is already apparent in some biomarker studies in which perhaps as many as 30% of clinical FTLD patients are also AD biomarker positive (Schoonenboom et al., 2012 ) and in diagnostic imaging assays used for dementia with Lewy bodies (DLB) where there may be significant overlap with FTD (Morgan et al., 2012 ).
1
—
—